Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
Study sponsor: RedHill Biopharma Limited
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-07-18Actual
Enrollment · participants475Actual
Source updated2025-07-31Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.